Get notified of page updates

Treatment study for people with advanced cancer with an APC or AXIN1 mutation

Clinicaltrials.gov identifier:
NCT06005974
PRINTER FRIENDLY PAGE

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

Treatment study for people with advanced cancer with an APC or AXIN1 mutation

Clinicaltrials.gov identifier:
NCT06005974
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or cancers with an or AXIN1 mutation. REC-4881 is a type of drug known as a MEK1/2 inhibitor. 

NOTE: This study is no longer recruiting patients. 

 

This Study is Open To:

NOTE: This study is no longer recruiting patients. 

This Study is NOT Open To:

NOTE: This study is no longer recruiting patients.